JP7461104B2 - Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 - Google Patents

Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 Download PDF

Info

Publication number
JP7461104B2
JP7461104B2 JP2018223465A JP2018223465A JP7461104B2 JP 7461104 B2 JP7461104 B2 JP 7461104B2 JP 2018223465 A JP2018223465 A JP 2018223465A JP 2018223465 A JP2018223465 A JP 2018223465A JP 7461104 B2 JP7461104 B2 JP 7461104B2
Authority
JP
Japan
Prior art keywords
compound
alkyl
minutes
independently selected
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018223465A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019099571A5 (enExample
JP2019099571A (ja
Inventor
仁 吉野
智史 土屋
篤 松尾
勉 佐藤
昌弘 西本
京子 小栗
紘子 小川
祥和 西村
佳之 古田
浩孝 柏木
伸行 堀
拓麻 家門
拓也 白石
昌伸 吉田
隆博 河合
智嗣 谷田
雅英 青木
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of JP2019099571A publication Critical patent/JP2019099571A/ja
Publication of JP2019099571A5 publication Critical patent/JP2019099571A5/ja
Priority to JP2024045935A priority Critical patent/JP7767492B2/ja
Application granted granted Critical
Publication of JP7461104B2 publication Critical patent/JP7461104B2/ja
Priority to JP2025182210A priority patent/JP2026016628A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018223465A 2017-11-29 2018-11-29 Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 Active JP7461104B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024045935A JP7767492B2 (ja) 2017-11-29 2024-03-22 Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
JP2025182210A JP2026016628A (ja) 2017-11-29 2025-10-29 Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017228661 2017-11-29
JP2017228661 2017-11-29

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024045935A Division JP7767492B2 (ja) 2017-11-29 2024-03-22 Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物

Publications (3)

Publication Number Publication Date
JP2019099571A JP2019099571A (ja) 2019-06-24
JP2019099571A5 JP2019099571A5 (enExample) 2022-01-06
JP7461104B2 true JP7461104B2 (ja) 2024-04-03

Family

ID=66975925

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018223465A Active JP7461104B2 (ja) 2017-11-29 2018-11-29 Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
JP2024045935A Active JP7767492B2 (ja) 2017-11-29 2024-03-22 Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
JP2025182210A Pending JP2026016628A (ja) 2017-11-29 2025-10-29 Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024045935A Active JP7767492B2 (ja) 2017-11-29 2024-03-22 Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
JP2025182210A Pending JP2026016628A (ja) 2017-11-29 2025-10-29 Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物

Country Status (1)

Country Link
JP (3) JP7461104B2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12234236B1 (en) 2023-09-14 2025-02-25 Ascletis Pharma (China) Co., Limited GLP-1R agonist and therapeutic method thereof
US12291530B1 (en) 2023-11-24 2025-05-06 Ascletis Pharma (China) Co., Limited GLP-1R agonist and therapeutic method thereof
US12709614B2 (en) 2023-09-14 2026-08-18 Ascletis Pharma (China) Co., Limited GLP-1R agonist and therapeutic method thereof

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110618208A (zh) * 2019-09-10 2019-12-27 威海迪素制药有限公司 一种（s）-（+）-3-羟基四氢呋喃对映异构体含量检测方法
PT4097099T (pt) 2020-02-07 2024-07-19 Gasherbrum Bio Inc Agonistas heterocíclicos de glp-1
KR20260040657A (ko) * 2020-07-20 2026-03-25 에코진 인크. 테트라히드로피라졸로-피라지닐-디히드로이미다졸론 또는 테트라히드로피라졸로-피리디닐-디히드로이미다졸론 화합물 및 그의 사용 방법
US20230322771A1 (en) * 2020-09-07 2023-10-12 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2022052958A1 (en) * 2020-09-10 2022-03-17 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
US20240366639A1 (en) * 2021-08-12 2024-11-07 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
SI4408840T1 (sl) 2021-09-27 2025-12-31 Terns Pharmaceuticals, Inc. Benzimidazolne karboksilne kisline kot agonisti GLP-1R
US12024507B2 (en) 2021-10-25 2024-07-02 Terns Pharmaceuticals, Inc. Compounds as GLP-1R agonists
AU2023224854A1 (en) 2022-02-23 2024-10-03 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
EP4522129A1 (en) * 2022-05-11 2025-03-19 Eli Lilly And Co. Glp1 pharmaceutical compositions
PE20250009A1 (es) * 2022-05-11 2025-01-07 Lilly Co Eli Composiciones de comprimidos de glp1
IL321449A (en) * 2022-12-13 2025-08-01 Lilly Co Eli Orforgliferon dosing regimen for the treatment of a patient with type 2 diabetes (T2D), obesity or overweight with at least one weight-related comorbidity
IL321043A (en) * 2022-12-15 2025-07-01 Sironax Ltd SARM1 modulators, their preparations and uses
IL321472A (en) 2022-12-19 2025-08-01 Lilly Co Eli Process for the production of GLP1 RA and intermediates therefor
US20260217707A1 (en) * 2023-01-17 2026-07-30 Fochon Biosciences, Ltd. Glp-1r agonists and uses thereof
KR20250168210A (ko) 2023-02-16 2025-12-02 가셔브룸 바이오, 인크. 헤테로시클릭 glp-1 효능제
PE20252787A1 (es) 2023-04-07 2025-12-22 Terns Pharmaceuticals Inc Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica
CN119630663B (zh) * 2023-06-29 2025-10-21 韦恩生物科技有限公司 一种glp-1受体激动剂及其制备方法和用途
TW202506108A (zh) * 2023-06-30 2025-02-16 大陸商正大天晴藥業集團股份有限公司 含多稠環結構的化合物
AU2024317579A1 (en) 2023-07-28 2026-02-05 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Benzo nitrogen-containing heterocyclic derivative regulator, preparation method therefor and use thereof
WO2025026436A1 (zh) * 2023-08-02 2025-02-06 韦恩生物科技有限公司 一种含氮并环化合物及其制备方法和用途
WO2025097835A1 (zh) * 2023-11-10 2025-05-15 重庆医药工业研究院有限责任公司 一种glp-1r激动剂化合物及其应用
KR20260118441A (ko) 2023-11-21 2026-07-30 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 헤테로시클릭 화합물, 이의 제조 방법 및 의약에서 이의 응용
AU2024394361A1 (en) * 2023-12-05 2026-06-18 Fortvita Biologics Inc. Glp-1 receptor targeting compounds and uses thereof
CN122438847A (zh) * 2023-12-14 2026-07-21 广东众生睿创生物科技有限公司 一种杂环glp-1受体激动剂及其应用
TW202602880A (zh) 2024-03-29 2026-01-16 美商拜歐美亞富成股份有限公司 雜環glp-1r促效劑
WO2025209515A1 (zh) * 2024-04-03 2025-10-09 广州市联瑞制药有限公司 一种glp-1受体激动剂及其制备方法和应用
WO2025261454A1 (zh) * 2024-06-19 2025-12-26 上海翰森生物医药科技有限公司 一种含氮大环化合物衍生物调节剂及其制备方法和应用
WO2026001866A1 (zh) * 2024-06-24 2026-01-02 联邦生物科技(珠海横琴)有限公司 一种glp-1受体激动剂及其应用
WO2026012449A1 (zh) * 2024-07-12 2026-01-15 联邦生物科技(珠海横琴)有限公司 一种具有glp-1受体激动剂效应的杂环化合物及其应用
WO2026032183A1 (en) * 2024-08-05 2026-02-12 Rongchang Pharmaceuticals, Ltd. Nitrogen-containing fused ring compound, pharmaceutical composition and use thereof
WO2026052129A1 (zh) * 2024-09-09 2026-03-12 中国科学院上海药物研究所 多环杂芳烃类glp-1受体激动剂
WO2026096330A1 (en) * 2024-10-28 2026-05-07 Merck Sharp & Dohme Llc Glp-1 receptor agonists and methods of use
WO2026103930A1 (zh) * 2024-11-18 2026-05-21 西藏海思科制药有限公司 一种咪唑-2-酮衍生物及其在医药上的应用
WO2026130384A1 (zh) * 2024-12-17 2026-06-25 上海翰森生物医药科技有限公司 一种苯并含氮杂环类衍生物、其制备方法和应用
WO2026145540A1 (zh) * 2024-12-31 2026-07-09 正大天晴药业集团股份有限公司 含多稠环结构的化合物的结晶及其制备方法
WO2026158231A1 (zh) * 2025-01-21 2026-07-30 歌礼制药(中国)有限公司 一种包含glp-1r激动剂的熔融颗粒及其药物组合物和制备方法
WO2026158353A1 (zh) * 2025-01-23 2026-07-30 联邦生物科技(珠海横琴)有限公司 具有glp-1受体激动剂效应的杂环化合物及其应用
WO2026158377A1 (zh) * 2025-01-24 2026-07-30 联邦生物科技(珠海横琴)有限公司 具有glp-1受体激动剂效应的杂环化合物及其应用
WO2026165082A1 (en) * 2025-01-28 2026-08-06 Ambrosia Biosciences Inc. Small molecule glp-1 agonists

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006510582A (ja) 2002-08-26 2006-03-30 武田薬品工業株式会社 カルシウム受容体調節化合物およびその用途
JP2010510987A (ja) 2006-11-27 2010-04-08 ハー・ルンドベック・アクチエゼルスカベット ヘテロアリールアミド誘導体
JP2012522060A (ja) 2009-03-30 2012-09-20 トランス テック ファーマ，インコーポレイテッド 置換アゾアントラセン誘導体、その医薬組成物とその使用の方法
WO2016038045A1 (en) 2014-09-08 2016-03-17 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Pyrazolopyridine derivatives and their use in therapy
JP2016508506A (ja) 2013-02-06 2016-03-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新しいインダニルオキシジヒドロベンゾフラニル酢酸
JP6567778B2 (ja) 2016-09-26 2019-08-28 中外製薬株式会社 Ｇｌｐ−１受容体アゴニスト作用を持つピラゾロピリジン誘導体

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006510582A (ja) 2002-08-26 2006-03-30 武田薬品工業株式会社 カルシウム受容体調節化合物およびその用途
JP2010510987A (ja) 2006-11-27 2010-04-08 ハー・ルンドベック・アクチエゼルスカベット ヘテロアリールアミド誘導体
JP2012522060A (ja) 2009-03-30 2012-09-20 トランス テック ファーマ，インコーポレイテッド 置換アゾアントラセン誘導体、その医薬組成物とその使用の方法
JP2016508506A (ja) 2013-02-06 2016-03-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新しいインダニルオキシジヒドロベンゾフラニル酢酸
WO2016038045A1 (en) 2014-09-08 2016-03-17 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Pyrazolopyridine derivatives and their use in therapy
JP6567778B2 (ja) 2016-09-26 2019-08-28 中外製薬株式会社 Ｇｌｐ−１受容体アゴニスト作用を持つピラゾロピリジン誘導体

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12234236B1 (en) 2023-09-14 2025-02-25 Ascletis Pharma (China) Co., Limited GLP-1R agonist and therapeutic method thereof
US12703700B2 (en) 2023-09-14 2026-08-11 Ascletis Pharma (China) Co., Limited GLP-1R agonist and therapeutic method thereof
US12709614B2 (en) 2023-09-14 2026-08-18 Ascletis Pharma (China) Co., Limited GLP-1R agonist and therapeutic method thereof
US12291530B1 (en) 2023-11-24 2025-05-06 Ascletis Pharma (China) Co., Limited GLP-1R agonist and therapeutic method thereof

Also Published As

Publication number Publication date
JP2024079762A (ja) 2024-06-11
JP7767492B2 (ja) 2025-11-11
JP2019099571A (ja) 2019-06-24
JP2026016628A (ja) 2026-02-03

Similar Documents

Publication Publication Date Title
JP7602573B2 (ja) Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体
JP7767492B2 (ja) Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
HK40004131B (en) Pyrazolopyridine derivative having glp-1 receptor agonist effect
NZ751725B2 (en) Pyrazolopyridine derivative having glp-1 receptor agonist effect
EA044109B1 (ru) Производные пиразолопиридина, обладающие эффектом агониста рецептора glp-1
HK40004131A (en) Pyrazolopyridine derivative having glp-1 receptor agonist effect

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20190516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190516

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211126

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220906

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230328

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231020

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240123

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240220

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240322

R150 Certificate of patent or registration of utility model

Ref document number: 7461104

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150